Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty

Arthropathy of Knee Clinical Trial

Official title:

Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03808155
• Other study ID #: GR20192021
• Status: Recruiting
• Phase: Phase 4
• Start date: August 1, 2019
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2023
• Source: Kantonsspital Graubünden
• Contact: Räto T. Strebel, PD Dr. med.
• Phone: +41 81 256 62 35
• Email: raeto.strebel[@]ksgr.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Various studies have shown that the risk of suffering a urinary retention after knee or hip prosthesis surgery is 10-80%. The aim of the study is to reduce this riks. For this purpose, it is investigated whether a previously known drug (tamsulosin) which is used in bladder emptying disorders, can achieve a reduction in urinary retention after surgery. After the patients agree to participate in the study, they are examined in our urological clinic. Uroflowmetry is performed with sonographic residual volume measurement and prostate volume measurement. Furthermore, a standardized Voiding questionaire (IPSS) is completed. This study is conducted as a double-blind study using a placebo control group. The drug / placebo is taken once a day, five days before and two days after surgery. Subsequently, it is observed whether it comes to a urinary retention or not. After the operation, no further urological checks are planned or needed.

Description:

Study Category and rationale:

This study uses a well-known drug (tamsulosin) which is authorised in Switzerland and widely used to treat obstructive voiding problems. In our case the indication is different from that specified in the prescribing information, but it is within the same disease group, which in our case is to prevent urinary retention. Therefore according to the legal ordinance on clinical trials (ClinO), this study is classified as a clinical trial, research with collection of health-related personal data and placebo controlled of the category B.

Objective:

Our goal is to reduce the rate of postoperative urinary retention after lower limb arthroplasty. For this purpose, we plan to investigate whether an already known drug (Tamsulosin), which is widely used for bladder emptying disorders, could reduce the rate of postoperative urinary retention.

Outcomes:

The primary outcome is the occurrence of urinary retention during the 48 postoperative hours. The secondary outcome is the influence of other clinical factors on the occurrence of urinary retention as type of anaesthesia, preoperative residual volume, prostate size and international prostate symptom score (IPSS).

Measurement and procedures:

Once the decision for lower limb arthroplasty is made during the planned orthopaedic consultation, the patient will receive a participant information sheet and the informed consent. If the patient is interested to take part in the study he will receive an appointment in the urological clinic at least six days before the operation. During the appointment a urological specialist will explain the entire study. A uroflowmetry with sonographic measurement of residual volume and prostate volume will be performed. Furthermore, the patient will fill out an IPSS-questionnaire. After the appointment the drug/placebo will be handed out to the patient, which should be taken once a day five days prior to the operation, on the day of surgery and two days thereafter.

Study product:

The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.

Control intervention:

Placebo.

Number of participants with rationale:

The number of participants projected for the entire study is 170. Thus 85 patients in the drug-treatment group and 85 patients for the placebo-treatment group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• male adults undergoing elective hip- or knee arthroplasty

Exclusion Criteria:

• women

• underage patients

• pre-existing treatment with tamsulosin or other prostate affecting medication

• patients who underwent transurethral resection of the prostate or prostatectomy

• patients with urethral strictures

• patients with neurological bladder dysfunction

• Known allergy to tamsulosin

• Hypotensive disorder

Related Conditions & MeSH terms

• Arthropathy of Hip
• Arthropathy of Knee
• Joint Diseases
• Urinary Retention
• Urinary Retention Postoperative

Intervention

Drug:
• Tamsulosin
The drug ist taken once a day per os five days prior to the operation and two days after the operation.
• Placebo Oral Tablet
The placebo ist taken once a day per os five days prior to the operation and two days after the operation.

Locations

Country	Name	City	State
Switzerland	Kantonsspital Graubünden	Chur	Graubünden

Sponsors (1)

Lead Sponsor	Collaborator
Kantonsspital Graubünden

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of urinary retention	The primary outcome is the occurrence of urinary retention during the 48 postoperative hours.	48 hours postoperatively
Secondary	Type of anaesthesia	Did the patient undergo general anaesthesia, spinal anaesthesia or regional anaesthesia	48 hours postoperatively
Secondary	Preoperative residual volume	Preoperatively the residual volume will be measured in milliliters (mL) by ultrasound.	Minimum 6 days before the planned operation.
Secondary	Prostate size	Preoperatively the prostate volume will be measured in milliliters (mL) by ultrasound.	Minimum 6 days before the planned operation.
Secondary	International prostate symptom score (IPSS).	The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).	Minimum 6 days before the planned operation.